Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

[1]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[2]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[3]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[4]  J. Barrett,et al.  Programmed death-ligand 1 (PD-L1) and immune infiltrates are prognostic for better outcome and enriched in the ATM (ataxia telangiectasia mutated)-low segment of gastric cancer (GC) , 2016 .

[5]  J. Barrett,et al.  Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC). , 2016 .

[6]  M. Reni,et al.  POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm). , 2016 .

[7]  E. Lowe,et al.  SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm). , 2016 .

[8]  I. Vergote,et al.  PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. , 2016 .

[9]  R. Plummer,et al.  An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib , 2016, Targeted Oncology.

[10]  M. O’Connor,et al.  Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.

[11]  Joon-Oh Park,et al.  Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Fasching,et al.  Abstract OT1-1-04: OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germlineBRCA1/2mutation (gBRCAm): , 2015 .

[13]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[14]  P. Fasching,et al.  331TiPOLYMPIA, NEO-OLYMPIA AND OLYMPIAD: RANDOMIZED PHASE III TRIALS OF OLAPARIB IN PATIENTS (PTS) WITH BREAST CANCER (BC) AND A GERMLINE BRCA1/2 MUTATION (GBRCAM). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. DiSilvestro,et al.  SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). , 2014 .

[16]  J. Ibdah,et al.  Characteristics of gastric cancer in Asia. , 2014, World journal of gastroenterology.

[17]  N. Sugimoto,et al.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Jager,et al.  Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors. , 2013 .

[19]  Y. Bang,et al.  Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients , 2013, Pathobiology.

[20]  P. Jeggo,et al.  The Heterochromatic Barrier to DNA Double Strand Break Repair: How to Get the Entry Visa , 2012, International journal of molecular sciences.

[21]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Lees-Miller,et al.  DNA damage-induced activation of ATM and ATM-dependent signaling pathways. , 2004, DNA repair.

[23]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[24]  B. Efron.  The Efficiency of Cox's Likelihood Function for Censored Data , 1977 .

[25]  N. Breslow.  Covariance analysis of censored survival data. , 1974, Biometrics.

[26]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[27]  Y. Bang,et al.  Ataxia‐telangiectasia‐mutated protein expression with microsatellite instability in gastric cancer as prognostic marker , 2014, International journal of cancer.